IMPACT Therapeutics Inks Exclusive Licensing Agreement with Pharmanovia for Senaparib in EMEA, Australia and New Zealand

Shots: IMPACT Therapeutics has entered into an exclusive licensing agreement with Pharmanovia for the exclusive rights to manufacture, develop, and commercialise senaparib in EMEA, Australia, and New Zealand As per the deal, Pharmanovia will acquire exclusive rights to manufacture, develop & commercialise senaparib across EMEA, Australia & New Zealand, with IMPACT eligible for upfront, regulatory & sales-based milestones of up to ~$496.77(€423.5M), plus tiered royalties up to the mid-twenties (%) on net sales. The partnership expands senaparib’s reach to 66 countries Senaparib is a PARP1/2 inhibitor developed by IMPACT, offering high target selectivity and a favorable safety profile Ref: PRNewsWire |  Image: IMPACT Therapeutics & Pharmanovia | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post IMPACT Therapeutics Inks Exclusive Licensing Agreement with Pharmanovia for Senaparib in EMEA, Australia and New Zealand appeared first on PharmaShots.